Obesity Collaboration Potential Skye’s nimacimab targets obesity with a planned Phase 2 in combination with the GLP-1R agonist Wegovy, signaling strong co‑development or licensing potential with large pharma players pursuing first‑in‑class metabolic therapies. The Halozyme collaboration and recent conference activity indicate external partner interest and a viable path to formal partnerships.

SC Delivery Opportunities Halozyme’s collaboration around higher‑dose subcutaneous administration for nimacimab highlights a market for delivery and manufacturing partnerships—engage CMOs, device providers, and formulation specialists to scale production and enable patient‑friendly dosing, potentially under exclusive or preferred supplier terms.

Industry Engagement Momentum Active engagement at GLP‑1 and obesity forums (GLP‑1 Therapeutics Summit, Keystone Obesity, ObesityWeek) creates a steady pipeline of BD leads. Leverage upcoming readouts and data packages to pursue joint development, co‑marketing, or licensing discussions with top pharma in the obesity space.

Risk‑Adjusted Deals With CFO turnover and a class‑action suit, potential licensors may favor milestone‑based, risk‑shared deal structures to reduce upfront risk while preserving upside; position Skye as a partner that offers clear data milestones and flexible terms.

Market Readiness Lean team, Nasdaq listing, and modest revenue imply a nimble partner capable of rapid execution in obesity/metabolic deals. Target mid‑to‑large pharma seeking to augment portfolios quickly with nimacimab through fast‑path agreements, scalable manufacturing options, and data‑driven milestones.